![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
![Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/683be916-2b6a-4719-b001-feea7e4130e9/gr1.jpg)
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
Eric Topol on X: "The BA.5 bivalent booster's effectiveness: by April 2023, "individuals previously vaccinated only with wild-type vaccines had little protection against Covid-19 hospital admission" restored by the booster (24K cases,
![Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC) Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC)](https://publichealthcollaborative.org/wp-content/uploads/2022/10/ENG_Twitter_updated-booster-doses-2.png)
Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC)
![Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-075286/F1.medium.jpg)
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
![Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm715152e1_BivalentVaccineEffectiveness_IMAGE_16Dec2022_1200x675.jpg?_=42783)
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
![Pfizer or Moderna - which is more effective as a COVID-19 booster shot? Findings from an MOH study - YouTube Pfizer or Moderna - which is more effective as a COVID-19 booster shot? Findings from an MOH study - YouTube](https://i.ytimg.com/vi/kPewSoG8BV8/maxresdefault.jpg)
Pfizer or Moderna - which is more effective as a COVID-19 booster shot? Findings from an MOH study - YouTube
![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/attachment/b611936d-5800-49ea-ab56-e932ddaa3aa7/gr1_lrg.jpg)
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
![Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/d32ad5c8-7d62-49cb-bf30-c48c5792fd8b/gr1_lrg.jpg)